Systematic Review and Meta-Analysis of Metabolic Changes Linked to Sacubitril/Valsartan Therapy
Clinical Scorecard: Systematic Review and Meta-Analysis of Metabolic Changes Linked to Sacubitril/Valsartan Therapy
At a Glance
| Category | Detail |
|---|
| Condition | Heart failure (HFrEF, HFmrEF, HFpEF), hypertension, chronic kidney disease |
| Key Mechanisms | Dual mechanism combining neprilysin inhibition and angiotensin II type-1 receptor blockade affecting vasoactive and metabolic peptides |
| Target Population | Patients receiving sacubitril/valsartan regardless of underlying condition |
| Care Setting | Cardiovascular and metabolic disease management in outpatient and inpatient settings |
Key Highlights
- Sacubitril/valsartan reduces mortality and hospital admissions in heart failure with reduced ejection fraction.
- The drug influences metabolic pathways including glycemic control and lipid metabolism through neprilysin inhibition.
- Evidence synthesis focuses on effects on glycemic indices (FBS, HbA1c) and lipid profiles (HDL, LDL, TG, TC).
Guideline-Based Recommendations
Diagnosis
- Consider sacubitril/valsartan for patients diagnosed with HFrEF, HFmrEF, or HFpEF.
- Evaluate baseline metabolic parameters including lipid profile and glycemic indices before initiation.
Management
- Use sacubitril/valsartan as part of heart failure management to improve cardiovascular outcomes.
- Monitor metabolic effects due to neprilysin inhibition impacting peptides involved in metabolism.
Monitoring & Follow-up
- Regularly assess lipid profiles (HDL, LDL, TG, TC) and glycemic markers (FBS, HbA1c) during therapy.
- Monitor for potential metabolic benefits or adverse effects in patients with cardiometabolic comorbidities.
Risks
- Be aware of possible metabolic alterations, both beneficial and adverse, associated with sacubitril/valsartan.
- Consider patient-specific factors such as diabetes, obesity, and chronic kidney disease when prescribing.
Patient & Prescribing Data
Patients with heart failure and cardiometabolic comorbidities including diabetes and CKD
Sacubitril/valsartan therapy is associated with changes in glycemic control and lipid metabolism, warranting metabolic monitoring.
Clinical Best Practices
- Implement baseline and follow-up metabolic assessments to evaluate the impact of sacubitril/valsartan.
- Use a multidisciplinary approach for patients with overlapping cardiovascular and metabolic disorders.
- Prefer longer follow-up and larger population data when interpreting metabolic effects from clinical studies.
References
